363 related articles for article (PubMed ID: 33945643)
1. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.
Nouveau L; Buatois V; Cons L; Chatel L; Pontini G; Pleche N; Ferlin WG
Eur J Immunol; 2021 Aug; 51(8):2074-2085. PubMed ID: 33945643
[TBL] [Abstract][Full Text] [Related]
2. "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor.
Kale SD; Mehrkens BN; Stegman MM; Kastelberg B; Carnes H; McNeill RJ; Rizzo A; Karyala SV; Coutermarsh-Ott S; Fretz JA; Sun Y; Koff JL; Rajagopalan G
Front Immunol; 2020; 11():1311. PubMed ID: 32676080
[TBL] [Abstract][Full Text] [Related]
3. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
[TBL] [Abstract][Full Text] [Related]
4. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
[No Abstract] [Full Text] [Related]
7. Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody.
Sugita S; Shimizu J; Makabe K; Keino H; Watanabe T; Takahashi M
Arthritis Res Ther; 2017 Jul; 19(1):176. PubMed ID: 28743289
[TBL] [Abstract][Full Text] [Related]
8. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
Iwata Y; Sasaki M; Harada A; Taketo J; Hara T; Akai S; Ishiguro T; Narita A; Kaneko A; Mishima M
Toxicol Appl Pharmacol; 2019 Sep; 379():114657. PubMed ID: 31326447
[TBL] [Abstract][Full Text] [Related]
9. Acute Systemic Infection with Dengue Virus Leads to Vascular Leakage and Death through Tumor Necrosis Factor-α and Tie2/Angiopoietin Signaling in Mice Lacking Type I and II Interferon Receptors.
Phanthanawiboon S; Limkittikul K; Sakai Y; Takakura N; Saijo M; Kurosu T
PLoS One; 2016; 11(2):e0148564. PubMed ID: 26844767
[TBL] [Abstract][Full Text] [Related]
10. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
11. An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice.
Forster K; Goethel A; Chan CW; Zanello G; Streutker C; Croitoru K
Gastroenterology; 2012 Nov; 143(5):1298-1307. PubMed ID: 22819863
[TBL] [Abstract][Full Text] [Related]
12. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA
Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
14. Development of a flow cytometry-based potency assay for prediction of cytokine storms induced by biosimilar monoclonal antibodies.
Madsen NH; Gad M; Larsen J
J Immunol Methods; 2022 Mar; 502():113231. PubMed ID: 35122772
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics.
Fletcher EAK; Eltahir M; Lindqvist F; Rieth J; Törnqvist G; Leja-Jarblad J; Mangsbo SM
Int Immunopharmacol; 2018 Jan; 54():1-11. PubMed ID: 29100032
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of interleukin-2 and interferon-gamma and maintenance of interleukin-4 and interleukin-10 production after administration of an anti-CD3 monoclonal antibody in mice.
Wissing KM; Desalle F; Abramowicz D; Willems F; Leo O; Goldman M; Alegre ML
Transplantation; 1999 Sep; 68(5):677-84. PubMed ID: 10507488
[TBL] [Abstract][Full Text] [Related]
17. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
18. Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk?
Van De Vyver AJ; Marrer-Berger E; Wang K; Lehr T; Walz AC
Clin Cancer Res; 2021 Nov; 27(22):6083-6094. PubMed ID: 34162679
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects.
Chavin KD; Qin L; Lin J; Kaplan AJ; Bromberg JS
Transplantation; 1993 Apr; 55(4):901-8. PubMed ID: 8097344
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
Yan H; Bhagwat B; Sanden D; Willingham A; Tan A; Knapton AD; Weaver JL; Howard KE
Toxicol Appl Pharmacol; 2019 Jun; 372():57-69. PubMed ID: 30914376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
